Melanoma Research Victoria

Richard D. Carvajal, MD: The other big category of toxicity is the cytokine release syndrome [CRS]-type symptoms.

Read the full story

Richard D. Carvajal, MD: Hello, my name is Richard Carvajal. I’m a medical oncologist at Columbia University Irving Medical Center in New York, New York.

Read the full story

Richard D. Carvajal, MD: We’ve had 2 dedicated clinical trials now for the uveal melanoma patient population, the 102 trial and then the 202 trial.

Read the full story

Richard D. Carvajal, MD: Let’s shift gears to tebentafusp, an immunotherapy where there is clear success. I wonder if you can describe for the audience how this drug works? What’s its mechanism?

Read the full story